Latest 8-K filings

Prime Medicine announced strong Q2 2026 results, highlighting regulatory advancements for PM577a and PM359, a favorable arbitration outcome for PM647, and a cash runway into 2027.

Globalstar reported second quarter 2026 results with a revenue decrease and a net loss, while noting progress on its merger with Amazon and record IoT subscriber activations.

USA TODAY Co. reported second quarter 2026 results showing an 8.3% year-over-year revenue decrease, but reaffirmed its full-year outlook with positive net income and free cash flow growth.

Hertz Global Holdings announced a 10% year-over-year revenue increase for Q2 2026, driven by record Revenue per Day and progress in its business transformation.

NextTrip announces the global expansion of its JOURNY TV platform, integrating GoUSA TV assets and a new partnership with KC Global Media to reach over 250 million viewers.

Playtika Holding Corp. announced its second quarter 2026 financial results, highlighting a 5.0% year-over-year revenue increase and significant growth in Adjusted EBITDA.

Guerrilla RF announced record second quarter 2026 revenue of $8.0 million, up 49% year-over-year, driven by a 142% surge in its catalog business, particularly aerospace and defense, while also exploring a Nasdaq Stock Market uplisting.

Aligos Therapeutics reported Q2 2026 results, highlighting a $25M upfront payment for pevifoscorvir sodium licensing and a $3M milestone for ALG-170675, alongside a reduced net loss but continued R&D investment.

Burford Capital announced its second-quarter 2026 financial results, highlighting record cash generation for the quarter and strong July portfolio momentum, despite a reported net loss driven by fair value adjustments.

Radian Group Inc. announced its second quarter 2026 financial results, highlighting a significant 93% year-over-year revenue increase driven by its transformation strategy and the inclusion of Inigo results, alongside record primary mortgage insurance in force.

Mira Pharmaceuticals announced positive toxicokinetic findings from a 7-day dog study for its obesity drug candidate SKNY-1, de-risking dose selection for future development.

Tejon Ranch Co. announced a substantial increase in second quarter 2026 net income and revenue, driven by strategic land sales and improved operational performance across segments.

Parker Hannifin announced record fiscal 2026 fourth quarter and full year results, exceeding prior year periods with significant sales and earnings growth, and issued optimistic guidance for fiscal year 2027.

Suburban Propane Partners, L.P. announced a third quarter fiscal 2026 net loss of $17.5 million, impacted by unseasonably warm temperatures.

Viatris Inc. announced second-quarter 2026 financial results, reporting total revenues of $3.8 billion with 5% reported growth and a U.S. GAAP net loss of $119 million, while raising full-year financial guidance.

Agenus Inc. announced second quarter 2026 financial results and provided an update on its Phase 3 ROBBIN trial for botensilimab (BOT) + balstilimab (BAL) in neoadjuvant MSS colon cancer, supported by an $85 million private placement.

Cars.com Inc. announced its second quarter 2026 financial results, showcasing a 1% year-over-year revenue increase to $179.9 million, a 103% surge in net income to $14.3 million, and a 4% rise in Adjusted EBITDA to $53.0 million.

Intellia Therapeutics reported positive Phase 3 HAELO trial data for lonvo-z in HAE, anticipates FDA BLA submission in H2 2026, and maintains a strong cash position extending into 2028.

Lantheus Holdings, Inc. announced its second quarter 2026 financial results and a definitive agreement to be acquired by Curium US Holdings LLC for up to $8.0 billion.

Sabre Corporation reported strong second quarter 2026 results, exceeding revenue and Adjusted EBITDA guidance, and raised its full-year Pro Forma Adjusted EBITDA and Free Cash Flow projections.

PepGen Inc. announced positive clinical trial updates for its PGN-EDODM1 drug candidate for Myotonic Dystrophy Type 1, including DSMB recommendation for dose escalation and a cash runway extending into late 2027.

ATI Inc. reported a strong second quarter of 2026, exceeding guidance with significant year-over-year growth in sales, net income, and adjusted EBITDA, leading to an increased full-year financial forecast.

Kelly Services announced second-quarter 2026 results, reporting a revenue of $1.0 billion, a 5.8% decrease year-over-year, with an improved underlying revenue decline of 0.6%.

Sunrise Realty Trust, Inc. announced its second quarter 2026 financial results, reporting GAAP net income of $3.1 million and Distributable Earnings of $3.9 million, while maintaining current loan status and exceeding dividends with earnings.

Distribution Solutions Group announced strong second quarter 2026 results with revenue up 11.0% year-over-year, alongside improved profitability, while also confirming a definitive merger agreement to go private.

BioVie Inc. announced positive topline results from its Phase 2 SUNRISE-PD trial evaluating bezisterim for early-stage Parkinson's disease, showing significant improvements in motor and non-motor symptoms and a favorable safety profile.

Payoneer Global Inc. announced its second quarter 2026 financial results, highlighting a 10% revenue increase (excluding interest income) and 15% volume growth, while also confirming its agreement to be acquired by Nuvei.

Sunstone Hotel Investors announced robust second-quarter results, exceeding expectations, and raised its full-year financial outlook following the sale of a San Francisco hotel and strategic share repurchases.

Climb Bio reported Q2 2026 financial results, highlighting progress in its CLYM116 and budoprutug programs, with key data readouts and trial initiations expected, alongside an extended cash runway into late 2028.

Ingles Markets, Inc. announced robust financial results for the first nine months of fiscal 2026, showcasing significant net income growth and increased gross profit, alongside a reduction in total debt.